WTX-124 initial Phase 1b expansion arm data showed 30% overall response rate as a monotherapy in a defined subset of post-ICI advanced or metastatic cutaneous melanoma patients, with potential best-in-class tolerability profile WTX-330 Phase 1b/2 trial initial data demonstrated additional evidence of antitumor activity and highly favorable tolerability profile, building upon monotherapy activity demonstrated in first-in-human Phase 1 clinical trial Additional Phase 1/1b data update for WTX-124 and completion of Part A of Phase 1b/2 clinical trial for WTX-330 are both expected in the first half of 2026 WTX-1011, Werewolf's first nominated INDUCER™ T cell engager development candidate targeting advanced, relapsed/refractory STEAP1-expressing cancers, continues to progress towards IND; with the announcement of Werewolf's second INDUCER development candidate, WTX-2022, targeting CDH6-expressing cancers, Werewolf is now planning for two INDs by mid-2027 WATERTOWN, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL) (the “Company” or “Werewolf”), an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions, today announced a pipeline update, including a review of recent data for its INDUKINE™ programs, and a business overview of its priorities for 2026 that includes a focus on the Company's highly differentiated INDUCER T cell engager platform.
